177 related articles for article (PubMed ID: 32546662)
1. Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
Trotta F; Avena P; Chimento A; Rago V; De Luca A; Sculco S; Nocito MC; Malivindi R; Fallo F; Pezzani R; Pilon C; Lasorsa FM; Barile SN; Palmieri L; Lerario AM; Pezzi V; Casaburi I; Sirianni R
Mol Cancer Ther; 2020 Sep; 19(9):1909-1921. PubMed ID: 32546662
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
3. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
[TBL] [Abstract][Full Text] [Related]
4. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
6. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
7. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Luconi M; Mannelli M
Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
[TBL] [Abstract][Full Text] [Related]
8. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
9. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
10. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Warde KM; Lim YJ; Ribes Martinez E; Beuschlein F; O'Shea P; Hantel C; Dennedy MC
Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35797592
[TBL] [Abstract][Full Text] [Related]
11. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
[TBL] [Abstract][Full Text] [Related]
12. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
13. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
17. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
18. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
20. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR; Acco A; Bach C; Bonatto SJR; de Figueiredo BC; de Souza LM
Br J Clin Pharmacol; 2021 Jul; 87(7):2698-2710. PubMed ID: 33382119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
